Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-65 lat
- •Nowo rozpoznana białaczka ostra mieloidalna lub zespół mielodysplastyczny, nigdy wcześniej nie leczony
- •Dobry stan ogólny (aktywny, w łóżku mniej niż 50% czasu)
- •Zdolność przyjmowania leków doustnie lub przez sondę
- •Prawidłowe funkcjonowanie nerek (clearance kreatyniny > 40 mL/min)
- •Prawidłowe funkcjonowanie wątroby
- •Chęć poddania się przeszczepowi szpiku kostnego
- •Test ciążowy ujemny (dla osób mogących zajść w ciążę)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
OHSU Knight Cancer Institute
Portland, United States
Trial contact
Curtis A. Lachowiez
Curtis A. Lachowiez
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.